China Approves Nvidia H200 Imports

China approves Nvidia H200 imports for major internet firms, easing export uncertainty and improving near-term demand visibility for Nvidia.

January 28, 2026·2 min read
View all news articles
Flat vector server rack with stacked AI chip, evoking China approves Nvidia H200 imports and limited cloud allocation.

KEY TAKEAWAYS

  • China approved first H200 batch for ByteDance, Alibaba and Tencent covering more than 400,000 units.
  • Selective allocation to private internet firms improves Nvidia demand visibility and reduces export uncertainty.
  • Regulators are accepting further H200 applications under a limited-access framework prioritizing domestic chip development.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

China approved imports of the first batch of Nvidia’s H200 AI GPUs, clearing more than 400,000 units mainly for ByteDance, Alibaba Group Holding, and Tencent Holdings. This marks a shift in access to advanced AI compute for Chinese cloud providers and industry customers.

Approvals and Allocations

The initial allocation prioritized private internet companies, while state-backed entities such as telecom operators face tighter controls under the approval framework. Chinese regulators are accepting applications for additional H200 approvals, with more firms expected to await decisions in the coming weeks. Authorities have set a framework to limit adoption and manage demand, aiming to protect domestic chip development.

Regulatory Context and Market Impact

The U.S. government granted export clearance for the H200 to vetted Chinese firms in December 2025. Nvidia’s H200 is the company’s second-most-powerful AI GPU, behind the restricted Blackwell B200. It outperforms the China-approved H20 and domestic alternatives like Huawei’s chips.

Chinese authorities initially rejected H200 imports and temporarily held shipments in early January 2026 as they weighed plans to strengthen domestic semiconductor capacity. Nvidia CEO Jensen Huang visited China during the week of January 20–26, 2026. Reports of the initial batch’s approval surfaced late on January 27 and into January 28.

This selective greenlight improves near-term demand visibility for Nvidia’s AI accelerators and reduces export uncertainty after U.S. clearance. Allocation to major cloud customers is likely to boost the company’s near-term sales prospects.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

AstraZeneca Camizestrant FDA Panel Rejects Candidate

AstraZeneca Camizestrant FDA Panel Rejects Candidate

AstraZeneca camizestrant FDA panel vote raises regulatory uncertainty and could pressure shares as the company consults U.S. regulators

Roku Q1 Earnings Raise Revenue Forecast

Roku Q1 Earnings Raise Revenue Forecast

Roku Q1 earnings showed accelerating ad and subscription momentum and drove management to raise the platform revenue forecast, likely lifting trading flows.

Rolls-Royce Keeps FY2026 Guidance Despite Mideast Risk

Rolls-Royce Keeps FY2026 Guidance Despite Mideast Risk

Rolls-Royce FY2026 guidance held after an April 30 trading update; rising flying hours and divisional order strength underpinned profit and cash targets.

Microsoft Q3 2026 Earnings Show AI Cloud Momentum

Microsoft Q3 2026 Earnings Show AI Cloud Momentum

Microsoft Q3 2026 earnings show a $37.0 billion AI run rate and robust Azure demand, prompting traders to shift into AI infrastructure and cloud exposure.

Roblox Cuts Guidance Amid Safety Costs

Roblox Cuts Guidance Amid Safety Costs

Roblox cuts guidance as safety initiatives and a legal settlement curb near-term user growth; Q1 showed revenue and bookings gains but outlook was trimmed.

Amgen Q1 Results: Tavneos Update as Sales Rise

Amgen Q1 Results: Tavneos Update as Sales Rise

Amgen Q1 results showed stronger sales and an EPS beat that lifted FY2026 guidance and may shift positioning amid a Tavneos FDA withdrawal proposal.